230 results
Page 4 of 12
8-K
EX-99.1
cls2cz2a9yv6 427q
30 Mar 22
KemPharm Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Corporate Updates
4:36pm
8-K
EX-99.1
ytajygdsfsbda31 y97l
21 Mar 22
KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial
8:49am
8-K
EX-99.1
uzt2viha
16 Mar 22
KemPharm team provided development and regulatory services to Corium pursuant to a master development services agreement
8:32am
424B3
cxf15
2 Feb 22
Prospectus supplement
4:16pm
POS AM
loki0 ce9
25 Jan 22
Prospectus update (post-effective amendment)
4:56pm
POS AM
EX-23.2
2qcdljz2z5z781pfvw0
25 Jan 22
Prospectus update (post-effective amendment)
4:56pm
424B3
m4hk5gw7se9m3
19 Jan 22
Prospectus supplement
9:43pm
8-K
EX-99.1
s4yefca4becwc1d7t49x
19 Jan 22
KemPharm Issues Letter to Shareholders Detailing Strategic Focus on CNS/Rare Disease Indications and Updated Clinical Development Strategy
4:27pm
424B3
pha0bd3g
10 Nov 21
Prospectus supplement
5:19pm
424B3
d0v8nxs1
10 Nov 21
Prospectus supplement
5:15pm
8-K
EX-99.1
ijum6tlre q2374
10 Nov 21
KemPharm Reports Third Quarter 2021 Financial Results and Corporate Updates
4:12pm
8-K
b9xbldkg0icr
10 Nov 21
KemPharm Reports Third Quarter 2021 Financial Results and Corporate Updates
4:12pm
8-K
EX-10.1
isyey
10 Nov 21
KemPharm Reports Third Quarter 2021 Financial Results and Corporate Updates
4:12pm
424B3
hd2g5 t3jkdcdnz
16 Aug 21
Prospectus supplement
12:00am
424B5
sdyvza ntevzzh
12 Jul 21
Prospectus supplement for primary offering
4:56pm
424B5
wz3j6re5fai
12 Jul 21
Prospectus supplement for primary offering
4:53pm
424B3
y9dv5i yfuheuvdl
12 Jul 21
Prospectus supplement
4:18pm
424B5
5l3u49b
7 Jul 21
Prospectus supplement for primary offering
4:50pm